Westfield Capital Management

SevOne, Inc. specializes in infrastructure performance monitoring and analytics solutions for a global clientele, including communications service providers, government entities, financial institutions, and large enterprises. The company offers a comprehensive suite of products, including the SevOne Data Platform, which gathers multi-vendor network performance metrics and flow data, and the SevOne Data Insight, designed for customizable visualizations and workflows. Additionally, the SevOne Data Appliance analyzes network and infrastructure data, while the SevOne Data Bus streams real-time data. The SevOne Data Cloud provides both real-time and historical insights from network telemetry. The company also has solutions for monitoring software-defined networking (SDN) and SD-WAN for managed services providers. Founded in 2003 and headquartered in Boston, Massachusetts, SevOne has expanded its presence with additional offices in Newark, Delaware, and London, United Kingdom. As of late 2019, SevOne operates as a subsidiary of Turbonomic, Inc.

Symform provides an innovative solution for distributed data management through its Cooperative Storage Cloud. This service allows users to access unlimited cloud storage and backup without incurring charges. The model is built on a simple premise: users contribute their unused server space in exchange for online storage. This reciprocal approach not only enhances disaster recovery and data security but also leverages the power of the Internet for efficient networking. Symform is responsible for the daily management of network security and the overall administration of the storage cloud, ensuring a seamless experience for its members.

Proteolix is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies targeting protein degradation pathways to address cancer and autoimmune diseases. The company’s lead product is a pioneering proteasome inhibitor, designed to evaluate safety and efficacy in treating multiple myeloma and various malignancies. In addition to this lead product, Proteolix is advancing a pipeline of novel proteasome inhibitors, which includes an oral formulation and a selective immunoproteasome inhibitor. These therapies aim to provide healthcare professionals with effective treatment options for specific hematologic cancers by inhibiting the cellular proteasome.

Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating chronic pain while addressing the concerns of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release profiles and safety of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol respectively, for managing severe pain and acute pain in adults. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions for patients with chronic pain, utilizing formulation improvements backed by strong intellectual property protections.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, founded in 2006. The company focuses on discovering and developing novel small-molecule drugs primarily for autoimmune and central nervous system disorders. Its key product candidates include CTP-543, currently in Phase III trials for alopecia areata; CTP-692, in Phase II trials for schizophrenia; and AVP-786, which is undergoing Phase III trials for various neurologic and psychiatric conditions, including agitation related to Alzheimer’s disease. Concert employs a unique precision deuterium chemistry platform to modify existing drug molecules, aiming to enhance efficacy and safety while reducing research and development risks. The company also maintains strategic collaborations with several pharmaceutical partners to further its research and development efforts.

Tepha, Inc. is a medical device company based in Lexington, Massachusetts, specializing in the development and manufacture of components utilizing proprietary biomaterial technology. The firm focuses on producing a new class of absorbable biomaterials known as polyhydroxyalkanoates (PHAs), which are engineered with recombinant DNA technology. Tepha's product offerings include monofilament sutures and meshes designed for various surgical applications, such as soft tissue approximation, hernia repair, and pelvic floor reconstruction. Additionally, the company provides the P4HB regenerative polymer scaffold for treating stress urinary incontinence, along with surgical films and composite meshes that facilitate tissue attachment and minimize complications. Tepha aims to address unmet medical needs across multiple fields by offering innovative solutions characterized by superior flexibility, elasticity, biocompatibility, and strength retention.

BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides for medical applications. The company focuses on creating proprietary therapeutic peptides and implantable devices designed to enhance bone and soft tissue repair, particularly in orthobiologics. Its flagship product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, serving as a surgical bone graft implant for various spinal and orthopedic surgeries, including lumbar degenerative disc disease and foot and ankle fusion procedures. Additionally, BioSET develops products for sports medicine and offers peptide signaling molecules along with diverse scaffold biomaterials to support musculoskeletal applications, including trauma and fracture repair. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating chronic pain while addressing the concerns of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release profiles and safety of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol respectively, for managing severe pain and acute pain in adults. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions for patients with chronic pain, utilizing formulation improvements backed by strong intellectual property protections.

Commerce.TV Corporation is a leading infrastructure provider for interactive television. The company provides end-to-end enhanced TV solutions for cable operators and programmers including digital set-top applications that provide news, entertainment and shopping services, in combination with the "CoreTVnet(TM)," an advanced database network for content delivery and response processing.